Alpha 1-antitrypsin deficiency primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Alpha 1-antitrypsin deficiency}}
{{Alpha 1-antitrypsin deficiency}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}
{{PleaseHelp}}


==Overview==
==Overview==

Revision as of 18:03, 22 January 2018

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency primary prevention

CDC on Alpha 1-antitrypsin deficiency primary prevention

Alpha 1-antitrypsin deficiency primary prevention in the news

Blogs on Alpha 1-antitrypsin deficiency primary prevention

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measures for the primary prevention of alpha 1-antitrypsin deficiency includes vaccination against hepatitis A and B is recommended to decrease the risk of liver disease.

Primary Prevention

Effective measures for the primary prevention of alpha 1-antitrypsin deficiency include:[1]

References

  1. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C (2005). "Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem". Chest. 128 (4): 1989–94. doi:10.1378/chest.128.4.1989. PMID 16236846.


Template:WikiDoc Sources